A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.
Testing for HPV infections in urine could be an extremely accurate way to exclude the possibility of such infections and screen for cervical cancer.
ASCO has released a clinical practice guideline on invasive cervical cancer. For the first time, ASCO created the guideline based on resource availability, tailoring recommendations to support basic- or limited-resource settings.
Women who do not engage in regular physical activity have an increased risk of developing cervical cancer, according to a new study
The American Society of Clinical Oncology released a statement calling for the rapid expansion of use of the human papillomavirus (HPV) vaccine to help protect thousands of people from HPV-associated cancers.
In this review, we will summarize clinical trials that have used various immunotherapeutic strategies, with a particular focus on recently emerging data for new agents and combinations.
Adolescent girls who live in predominantly Hispanic and high poverty communities are more likely to have had at least one HPV vaccine dose compared to girls in low poverty communities and those with different ethnic make up.
Small- and large-cell neuroendocrine tumors of the cervix are exceedingly rare and exceedingly aggressive.
In this interview we discuss the latest on HPV vaccines for cancer prevention and some of the struggles countries face in achieving widespread adoption.
An investigational vaccine has shown activity as a therapeutic treatment for high-grade pre-cancerous cervical lesions caused by the human papillomavirus.